CUTANEOUS T-CELL LYMPHOMA
Clinical trials for CUTANEOUS T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for CUTANEOUS T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a combination of four drugs (romidepsin, CC-486, dexamethasone, and lenalidomide) in 26 adults with T-cell cancers that had come back or stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Rese…
Matched conditions: CUTANEOUS T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
Experimental combo aims to boost stem cell transplant success for rare blood cancers
Disease control CompletedThis early-phase study tested whether adding the drug romidepsin to standard chemotherapy before and after a stem cell transplant could help control T-cell cancers like lymphoma and leukemia. Researchers enrolled 23 adults to find the safest dose and see if the combination helped…
Matched conditions: CUTANEOUS T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:52 UTC
-
Light-Activated ointment shows promise for rare skin cancer
Disease control CompletedThis study tested a synthetic ointment called hypericin (HyBryte) combined with visible light to treat mycosis fungoides, a rare type of skin lymphoma. Ten adults with early-stage disease applied the ointment and received light treatments every 6 weeks for up to 54 weeks. The goa…
Matched conditions: CUTANEOUS T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Ellen Kim, MD • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Real-World study checks how CTCL drug performs outside clinical trials
Knowledge-focused CompletedThis study looked at 100 adults with cutaneous T-cell lymphoma (CTCL) who had already tried at least one other treatment. Researchers wanted to see how well the drug mogamulizumab works in everyday medical practice, not just in controlled trials. They measured how many patients h…
Matched conditions: CUTANEOUS T-CELL LYMPHOMA
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC